Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

194
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
194
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

20
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
20
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

236
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
236
Hyperpnea and Hyperventilation01:25

Hyperpnea and Hyperventilation

1.1K
Hyperventilation refers to a higher-than-normal rate and depth of breathing, often associated with anxiety attacks. This excessive breathing surpasses the body's need to expel CO2, leading to a condition known as hypocapnia - an unusually low level of carbon dioxide in the blood. Hypocapnia can constrict cerebral blood vessels, reducing blood flow to the brain, which may result in dizziness or fainting. Early signs include tingling and muscle spasms in the hands and face, caused by falling...
1.1K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

164
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
164

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of riociguat in early pulmonary vascular disease (ESRA): a prospective, multicenter, randomized, double-blind, placebo-controlled phase IIa trial.

Chest·2026
Same author

Effect of sildenafil on resting and exercise haemodynamics in hypoxia in patients with pulmonary vascular diseases: data from a randomised controlled trial.

ERJ open research·2026
Same author

Ventilatory Efficiency During Exercise in CTEPH and PAH Pre- and Post-Treatment.

Pulmonary circulation·2026
Same author

The effect of a two-day stay at high altitude (2500 m) on right ventricular afterload and oxygen delivery in patients with pulmonary vascular disease A randomized controlled crossover trial.

Chest·2026
Same author

Long-term outcomes of home mechanical ventilation in Duchenne Muscular Dystrophy - an observational study.

Respiratory medicine·2026
Same author

The effect of high altitude on exercise capacity and cardiorespiratory function in patients with pulmonary vascular disease after an overnight stay at 2500 m: a randomised crossover study.

ERJ open research·2026

Related Experiment Video

Updated: Jul 12, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

[Vaskuläre Dyspnoe: Pulmonale Hypertonie].

Dora Serény1, Silvia Ulrich1, Charlotte Berlier2

  • 1Klinik für Pneumologie, UniversitätsSpital Zürich, Zürich.

Therapeutische Umschau. Revue Therapeutique
|October 19, 2023
PubMed
Summary

Pulmonary hypertension (PH) diagnosis requires right heart catheterization to measure pressures and resistance. Treatment varies by PH type, with specific therapies for pulmonary arterial hypertension and chronic thromboembolic PH.

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices
13:32

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices

Published on: January 14, 2014

10.8K

Related Experiment Videos

Last Updated: Jul 12, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices
13:32

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices

Published on: January 14, 2014

10.8K

Area of Science:

  • Cardiology and Pulmonology
  • Hemodynamics
  • Diagnostic Imaging

Context:

  • Pulmonary hypertension (PH) is defined as mean pulmonary artery pressure > 20 mmHg.
  • Echocardiography screens for PH, but right heart catheterization confirms diagnosis and measures key hemodynamic parameters.
  • PH classification includes precapillary, postcapillary, and combined forms based on PAWP and PVR.
  • Supportive therapies like diuretics and oxygen are common, while specific treatments target pulmonary arterial hypertension and CTEPH.

Purpose:

  • To outline the diagnostic criteria and therapeutic approaches for pulmonary hypertension (PH).
  • To differentiate between various PH classifications based on hemodynamic measurements.
  • To highlight the complexity of PH management, emphasizing the need for specialized centers.

Summary:

  • Right heart catheterization is essential for diagnosing PH by measuring pulmonary arterial pressures, PAWP, CO, and PVR.
  • PH is categorized into precapillary, postcapillary, and combined types based on PAWP and PVR thresholds.
  • Treatment strategies are tailored to PH type, including supportive care and specific interventions for pulmonary arterial hypertension and CTEPH.

Impact:

  • Accurate PH diagnosis and classification are crucial for effective treatment selection.
  • Understanding hemodynamic parameters guides therapeutic decisions in complex PH cases.
  • Management of PH, particularly pulmonary vascular diseases, necessitates expertise found in specialized centers.